TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
The European Commission has approved the cholesterol-lowering medication alirocumab (Praluent; Sanofi/Regeneron) to reduce cardiovascular (CV) risk by lowering low-density-lipoprotein cholesterol (LDL ...
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent (alirocumab) injection met its primary endpoint showing low-density ...
The FINANCIAL — Sanofi and Regeneron Pharmaceuticals, Inc. on June 10 announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback